Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

Study Z-033

The first multi-center efficacy trial Z-033 was conducted in 53 sites in the United States and Canada, with 8 additional sites in Europe. The study involved 667 patients under the supervision of lead investigator, Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York. Patients entered a 1- to 4-week screening period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients were then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients were administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 (for treatment Arm A, those in Arm B received IM injection at week 0, 2 and 26 followed by placebo at Week 28). Patients in treatment Arm C received placebo injections at Week 0, 2, 26 and 28. All patients were followed up to Week 52.

The study Z-033 demonstrated no clear differences in overall efficacy with all 3 groups showing an improvement in IPSS of approximately 4 points that was maintained throughout the 52 weeks. There was a slight advantage in favor of the main active treatment arm (Arm A) up to Week 46 of the follow-up, which was no longer de
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Nev. , Sept. 17, 2014  PDL BioPharma, Inc. ... its independent registered accounting firm, Ernst & Young LLP ("EY") ... was confirmed in a letter delivered to the Company on ... on September 16, 2014.  PDL has issued ... "We have received a number of inquiries on the reason ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... NEWTOWN, Pa. , Sept. 17, 2014 ... services and eClinical Solutions, today announced three of its ... Conference for Clinical Data Management to be held ... Vegas, Nevada . The Company also announced the ... to raise overall quality in clinical trials acquired earlier ...
(Date:9/17/2014)... 2014 Alternative Fuels Americas, Inc. (AFAI) announced today ... Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... The SPV shall be called AFAI Jatro Green Ethiopia and ... shareholder. The SPV shall pursue Jatropha planting and biofuels production ... Ethiopia . "Although we have experienced ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... U.S. ... business, BOSTON, MA ... Hand, the world,s first commercially,available bionic hand, today announced that it has ... the,United States., Bill Graham has been named U.S. sales manager for ...
... PLC Systems Inc.,(Amex: PLC ) today announced that ... Conference on February 18-21, 2008 at the Ritz,Carlton Laguna Niguel ... 20th beginning at 3:30 pm local time. Presenting for the ... webcast of the presentation will be available at the company,s,website ...
... Open DICOM Standard DR and Data Management Systems Spurs ... Forty-Five Percent Growth for Company, ... a,leading developer of digital radiography (DR), PACS (Picture Archiving and,Communications ... the company,s revenues grew 45 percent,to surpass $35 million for ...
Cached Biology Technology:Touch Bionics adds to sales, marketing, production and design teams 2Touch Bionics adds to sales, marketing, production and design teams 3PLC Systems to Present at the ROTH Conference 2Eklin Medical Reports Record Revenues for 2007 2Eklin Medical Reports Record Revenues for 2007 3
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/17/2014)... reproductive technologies, the justice and well-being of our ... identify key issues, articulate their values and concerns, ... defensible ways forward. But what are the best ... Hastings Center and the Presidential Commission for the ... publish a series of essays to highlight the ...
(Date:9/17/2014)... A rare genetic disorder known as Jacobsen syndrome has ... investigation by researchers at San Diego State University and ... suggesting better treatment options for people with Jacobsen syndrome, ... underpinnings of autism., Jacobsen syndrome affects approximately 1 in ... It occurs in a person when there is a ...
Breaking Biology News(10 mins):How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3A link between Jacobsen syndrome and autism 2
... Scientists across the world are building an extensive repository ... understanding the function of the approximately 57,000 genes that ... Rice Functional Genomics Consortium recently announced the public availability ... mutations in about half of the known functional genes ...
... people are affected with retinitis pigmentosa (RP), a disease ... blindness. Now, a University of Missouri researcher has identified ... different forms of RP. This discovery will help scientists ... humans. "The same genetic mutations ...
... WASHINGTON, DC As researchers continue to examine ... ,important that people understand the differences among various ... Corn Refiners Association (CRA). Interchanging two distinctly different ... corn syrup, creates factually incorrect conclusions and misleads ...
Cached Biology News:200,000 rice mutants available worldwide for scientific investigation 2Cats' eye diseases genetically linked to diseases in humans 2Pure fructose frequently confused with high fructose corn syrup 2